The role of HER2/neu, BCL2, p53 genes and proliferating cell nuclear protein as molecular prognostic parameters in localized prostate carcinoma

Fonseca, Gilvan N.; Srougi, Miguel; Leite, Kátia Ramos Moreira; Nesrallah, Luciano J.; Ortiz, Valdemar

doi:10.1590/s1516-31802004000300009

Cited by 10 publications

(17 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our findings confirmed the reports of Karaburun et al [28]. But they contradict the observations of Fonseca et al [29] of a positive correlation between p53 expression and both an increasing PSA level and clinical stage. We also noted a significant positive correlation between p53 labeling index and Ki-67 labeling index (R = 0.35, p < 0.005), confirming that the mutated gene p53 protein loses the ability to inhibit cell proliferation.…”

Section: Discussion Discussion Discussion Discussionsupporting

confidence: 78%

Comparative analysis of biological profiles of benign prostate hyperplasia and prostate cancer as potential diagnostic, prognostic and predictive indicators

Makarewicz¹,

Żyromska²,

Andrusewicz³

2011

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

Section: Discussion Discussion Discussion Discussionsupporting

confidence: 78%

Comparative analysis of biological profiles of benign prostate hyperplasia and prostate cancer as potential diagnostic, prognostic and predictive indicators

Makarewicz¹,

Żyromska²,

Andrusewicz³

2011

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

“…In a previous study [21], we evaluated the presence of BCL2 and BAX-expressing cells in cervical lesions, according the degree of lesions, and BCL2 expression was observed mainly in HSIL women when compared with LSIL and control groups, favoring carcinogenesis. In accordance, BCL2 expression was associated with decreased survival in leukemia and prostate cancer [28,29], whereas in colorectal [30,31] and breast cancer, it was related to favorable outcome.…”

Section: Discussionmentioning

confidence: 68%

“…All statistical tests were two-sided, a p value of 0.05 was considered significant, and analyses were performed using Epi Info 6 (Version 6.04, July 1996), SNPStats [29], and SPSS (Version 16, September 2007).…”

Section: Discussionmentioning

confidence: 99%

Polymorphism in apoptotic BAX (-248G>A) gene but not in anti-apoptotic BCL2 (-938C>A) gene and its protein and mRNA expression are associated with cervical intraepithelial neoplasia

et al. 2015

View full text Add to dashboard Cite

HPV is associated with cervical cancer and plays a crucial role in tumor formation. Apoptosis is regulated by different pathways involving genes that either promote (BCL2 gene) or inhibit (BAX gene) cell death. Our goal was to determine whether the BCL2-938C>A (rs2279115) and BAX-248G>A (rs4645878) single nucleotide polymorphisms (SNPs) are associated with squamous intraepithelial neoplasia (SIL) risk, and whether their phenotypic expression was impaired in these lesions. Two hundred and thirty-one cases showing SIL were classified as low SIL (LSIL, n = 101) or high SIL (HSIL, n = 130), and control subjects (n = 266) with no gynecologically proven SIL were recruited. No statistical difference in the genotype and allelic frequency of the BCL-2-938C>A polymorphism was observed among the groups. BCL2-938C/A and A/A homozygotes carriers had higher distribution of BCL-2-expressing cells in stroma in the SIL group. BCL2 mRNA-expression was not correlated with BCL2-938C>A SNPs in both groups. We did find a strong association of the BAX GG genotype and risk for SIL. No difference was observed between LSIL and HSIL groups. In BAX-248G/A and A/A homozygote carriers, the number of BAX-expressing cells was lower the epithelium area in SIL. However, mRNA expression was higher in SIL patients than in the control group. In conclusion, our data provide evidence that allele G carriers in the BAX-248G>A promoter SNP may influence the development of SIL. However, this genotype does not influence the SIL outcome. Additionally, we suggest a possible role of HPV infection in the inhibition of the expression of BAX protein, decreasing cell death, and favoring cervical carcinogenesis.

show abstract

“…Moreover, abnormal bcl-2 or bax expression was not significantly associated with Gleason Score or stage; although a borderline relationship of bax expression to Gleason Score was observed (Table 3). While some relationships of these biomarkers to Gleason Score have been reported (9,(22)(23)(24), this has not been a consistent finding (25)(26)(27). In a report of patients with Stage B, C, or D disease, Amirghofran et al (28) found that bax, but not bcl-2 expression, was significantly related to prostate carcinoma stage (p = 0.031); no correlation to Gleason Score was observed for either biomarker.…”

Section: Discussionmentioning

confidence: 95%

Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10

Khor

DeSilvio

et al. 2006

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Purpose-Bcl-2 and bax are proteins with opposing roles in apoptosis regulation; yet abnormal expression of either has been associated with failure after radiotherapy (RT). In this study we examined bcl-2 and bax expression as predictive markers in men treated with radiotherapy ± androgen deprivation on Radiation Therapy Oncology Group (RTOG) protocol 86-10.Experimental Design-Suitable archival diagnostic tissue was obtained from 119 (26%) patients for bcl-2 analysis and 104 (23%) patients for bax analysis. Cox proportional hazards multivariate analysis was used to determine the relationship of abnormal bcl-2 and bax expression to the end points of local failure, distant metastasis, cause-specific mortality, and overall mortality. Bcl-2 overexpression was classified as any tumor cell cytoplasmic staining and altered bax expression was classified as greater or lesser cytoplasmic staining intensity of tumor cells as compared with adjacent normal prostate epithelium.Results-The study cohort exhibited bcl-2 overexpression in 26% (n = 30) of cases and abnormal bax expression in 47% (n = 49) of cases. A borderline significant relationship was observed between abnormal bax expression and higher Gleason score (p = 0.08). In univariate and multivariate analyses, there was no statistically significant relationship seen between abnormal bcl-2 or bax expression and outcome. Conclusions-Abnormal bcl-2 and bax expression were not related to any of the end points tested. The cohort examined was comprised of patients with locally advanced disease and it is possible that these markers may be of greater value in men with earlier-stage prostate cancer.

show abstract

The role of HER2/neu, BCL2, p53 genes and proliferating cell nuclear protein as molecular prognostic parameters in localized prostate carcinoma

Cited by 10 publications

References 30 publications

Comparative analysis of biological profiles of benign prostate hyperplasia and prostate cancer as potential diagnostic, prognostic and predictive indicators

Comparative analysis of biological profiles of benign prostate hyperplasia and prostate cancer as potential diagnostic, prognostic and predictive indicators

Polymorphism in apoptotic BAX (-248G>A) gene but not in anti-apoptotic BCL2 (-938C>A) gene and its protein and mRNA expression are associated with cervical intraepithelial neoplasia

Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10

Contact Info

Product

Resources

About